2363-PUB: The Efficacy of Low vs. High FDA-Approved SGLT2 Inhibitor Dose Compared with DPP-4 Inhibitors: A Meta-analysis
UHRIG, JARROD, MISHRIKY, BASEM M., PAGE, STEPHANIE O., SEWELL, KERRY, POWELL, JAMES R., PATIL, SHIVAJIRAO P., CUMMINGS, DOYLE M.
Published in Diabetes (New York, N.Y.) (01.06.2019)
Published in Diabetes (New York, N.Y.) (01.06.2019)
Get full text
Journal Article
2365-PUB: Can Baseline Hemoglobin A1c Help Guide Treatment with an SGLT2i vs. DPP-4i? A Meta-analysis
PAGE, STEPHANIE O., MISHRIKY, BASEM M., UHRIG, JARROD, SEWELL, KERRY, MIAN, MUNA R., POWELL, JAMES R., CUMMINGS, DOYLE M.
Published in Diabetes (New York, N.Y.) (01.06.2019)
Published in Diabetes (New York, N.Y.) (01.06.2019)
Get full text
Journal Article
Should Baseline Hemoglobin A 1c or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic Review
Uhrig, Jarrod L, Page, Stephanie O, Mishriky, Basem M, Patil, Shivajirao P, Powell, James R, Sewell, Kerry, Mian, Muna R, Cummings, Doyle M
Published in Journal of clinical pharmacology (01.08.2020)
Published in Journal of clinical pharmacology (01.08.2020)
Get more information
Journal Article